What is hepatitis C ? Hepatitis is inflammation of the liver. Inflammation is swelling that happens when tissues of the body are injured or infected. Inflammation ...
This page contains affiliate links. If you click a link and make a purchase or sign up for a service, Online Health Directory may earn a commission at no additional cost to you. We only recommend services we believe provide genuine value. For full details, see our Affiliate Disclosure page.
What is hepatitis C ? Hepatitis is inflammation of the liver. Inflammation is swelling that happens when tissues of the body are injured or infected. Inflammation can damage organs. There are different types of hepatitis . One type, hepatitis C , is caused by the hepatitis C virus (HCV). Hepatitis C can range from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis C can be acute or chronic: Acute hepatitis C is a short-term infection. The symptoms can last up to 6 months. Sometimes your body is able to fight off the infection and the virus goes away. But for most people, an acute infection leads to chronic infection. Chronic hepatitis C is a long-lasting infection. If it is not treated, it can last for a lifetime and cause serious health problems, including liver damage, cirrhosis (scarring of the liver), liver cancer, and even death. How is hepatitis C spread? Hepatitis C spreads through contact with the blood of someone who has HCV. This contact may be through: Sharing drug needles or other drug materials with someone who has HCV. In the United States, this is the most common way that people get hepatitis C . Getting an accidental stick with a needle that was used on someone who has HCV. This can happen in health care settings. Being tattooed or pierced with tools or inks that were not sterilized after being used on someone who has HCV. Having contact with the blood or open sores of someone who has HCV. Sharing personal care items that may have come in contact with another person's blood, such as razors or toothbrushes. Being born to a mother with HCV. Having unprotected sex with someone who has HCV. Before 1992, hepatitis C was also commonly spread through blood transfusions and organ transplants. Since then, there has been routine testing of the U.S. blood supply for HCV. It is now very rare for someone to get HCV this way. Who is more likely to get hepatitis C ? You are more likely to get hepatitis C if you: Have injected drugs Had a blood transfusion or organ transplant before July 1992 Have hemophilia and received clotting factor before 1987 Have been on kidney dialysis Have been in contact with blood or infected needles at work Have had tattoos or body piercings Have worked or lived in a prison Were born to a mother with hepatitis C Have HIV Have had more than one sex partner in the last 6 months Have had a sexually transmitted infection (STI) Are a man who has had sex with men (MSM) If you are at high risk for hepatitis C , your health care provider will likely recommend that you get tested for it. What are the symptoms of hepatitis C ? Most people with hepatitis C have no symptoms. Some people with acute hepatitis C do have symptoms within 1 to 3 months after they are exposed to the virus. These symptoms may include: Dark yellow urine Fatigue Fever Gray- or clay-colored stools Joint pain Loss of appetite Nausea and/or vomiting Pain in your abdomen (belly) Jaundice (yellowish eyes and skin) If you have chronic hepatitis C , you probably will not have symptoms until it causes complications. This can happen decades after you were infected. For this reason, hepatitis C screening is important, even if you have no symptoms. What other problems can hepatitis C cause? Without treatment, hepatitis C may lead to cirrhosis, liver failure, and liver cancer. Early diagnosis and treatment of hepatitis C can prevent these complications. How is hepatitis C diagnosed? Providers diagnose hepatitis C based on your medical history, a physical exam, and blood tests. If you do have hepatitis C , you may need additional tests to check for liver damage. These tests may include other blood tests, an ultrasound of the liver, and a liver biopsy. What are the treatments for hepatitis C ? Treatment for hepatitis C is with antiviral medicines. They can cure the disease in most cases. If you have acute hepatitis C , your provider may wait to see if your infection becomes chronic before starting treatment. If your hepatitis C causes cirrhosis, you should see a doctor who specializes in liver diseases. Treatments for health problems related to cirrhosis include medicines, surgery, and other medical procedures. If your hepatitis C leads to liver failure or liver cancer, you may need a liver transplant. Can hepatitis C be prevented? There is no vaccine for hepatitis C . But you can help protect yourself from hepatitis C infection by: Not sharing drug needles or other drug materials. Wearing gloves if you have to touch another person's blood or open sores. Making sure your tattoo artist or body piercer uses sterile tools and unopened ink. Not sharing personal items such toothbrushes, razors, or nail clippers. Using a latex condom during sex. If your or your partner is allergic to latex, you can use polyurethane condoms. NIH: National Institute of Diabetes and Digestive and Kidney Diseases Health topic information sourced from MedlinePlus, a service of the National Library of Medicine, National Institutes of Health.
Health topic information on this page is sourced from MedlinePlus, a service of the National Library of Medicine, National Institutes of Health. Visit medlineplus.gov for more information.
FDA-approved medications commonly prescribed for hepatitis c. This is not medical advice — a clinician decides which treatment fits your situation.
1 INDICATIONS AND USAGE REBETOL is a nucleoside analogue indicated in combination with interferon alfa-2b (pegylated and nonpegylated) for the treatment of Chronic Hepatitis C (CHC) in patients 3 years of age or older with compensated liver disease. ( 1.1 ) Patients with the following characteristics are less likely to benefit from re-treatment after failing a course of therapy: previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and…
BLACK BOX WARNING: WARNING: EMBRYO-FETAL TOXICITY, HEMOLYTIC ANEMIA, and MONOTHERAPY NOT RECOMMENDED Significant teratogenic and embryocidal effects have been demonstrated in all animal species exposed to ribavirin. In addition, ribavirin has a multiple-dose half-life of 12 days and may persist in…
1 INDICATIONS AND USAGE Eltrombopag is a thrombopoietin receptor agonist indicated: for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag tablets should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. ( 1.1 ) for the treatment of…
BLACK BOX WARNING: WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C and RISK OF HEPATOTOXICITY In patients with chronic hepatitis C, eltrombopag in combination with interferon and ribavirin may increase the risk of hepatic decompensation [see Warnings and Precautions…
Manufacturer: Amneal Pharmaceuticals NY LLC
Recruiting trials that involve hepatitis c. Trial status changes often — always confirm with the trial coordinator before traveling.
No recruiting clinical trials are listed for this condition right now. Search ClinicalTrials.gov directly for the most current list.
A gastroenterologist is typically the right starting point for hepatitis c.
Browse gastroenterologists by city →No spam. Unsubscribe any time.
By subscribing you agree to our Privacy Policy. We will never share your data with third parties.
Skip the waiting room and connect with a licensed US doctor for hepatitis c questions and prescriptions where appropriate.
This page provides general health information for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
1 INDICATIONS AND USAGE Ribavirin is a nucleoside analogue indicated for the treatment of chronic hepatitis C (CHC) virus infection in combination with peginterferon alfa-2a in patients 5 years of age and older with compensated liver disease not previously treated with interferon alpha, and in adult CHC patients coinfected with HIV ( 1 ) Ribavirin tablets in combination with peginterferon alfa-2a are indicated for the treatment of patients 5 years of age and older with chronic hepatitis C…
BLACK BOX WARNING: WARNING: RISK OF SERIOUS DISORDERS AND RIBAVIRIN-ASSOCIATED EFFECTS WARNING: RISK OF SERIOUS DISORDERS AND RIBAVIRINASSOCIATED EFFECTS See full prescribing information for complete boxed warning. Ribavirin monotherapy, including ribavirin, is not effective for the treatment of…
1 INDICATIONS AND USAGE PegIntron is an antiviral indicated for treatment of Chronic Hepatitis C (CHC) in patients with compensated liver disease. ( 1.1 ) 1.1 Chronic Hepatitis C (CHC) PegIntron ® , as part of a combination regimen, is indicated for the treatment of Chronic Hepatitis C (CHC) in patients with compensated liver disease. PegIntron in combination with REBETOL ® (ribavirin) and an approved Hepatitis C Virus (HCV) NS3/4A protease inhibitor is indicated in adult patients with HCV…
BLACK BOX WARNING: WARNING: RISK OF SERIOUS DISORDERS AND RIBAVIRIN-ASSOCIATED EFFECTS Alpha interferons, including PegIntron, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic…
INDICATIONS AND USAGE RIBASPHERE (ribavirin, USP) in combination with peginterferon alfa-2a is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).
BLACK BOX WARNING: RIBASPHERE (ribavirin, USP) monotherapy is not effective for the treatment of chronic hepatitis C virus infection and should not be used alone for this indication (see WARNINGS ). The primary clinical toxicity of ribavirin is hemolytic anemia. The anemia associated with…